Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-ascending-dose IV infusion study of ABP-700 in healthy volunteers
NL-OMON41980Phase 1Active, not recruiting
- Sponsor
- Annovation Biopharma
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of moxetomidate in Not applicable (3 arms), sponsored by Annovation Biopharma. Primary endpoints: Safety and tolerability and Maximum tolerated dose. Started Aug 2014; status: active, not recruiting.
02
Drugs
moxetomidate
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON41980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41980.